ZNTL stock forecast, quote, news & analysis
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more
Why Zentalis Pharmaceuticals (ZNTL) Stock Is Down -23.6% in the Last 30 Days
Key Takeaways
- ZNTL shares declined roughly 23.6% over the last 30 days, sliding from a $3.11 close on September 18, 2026, to about $2.38 by October 20, 2026.
- The pullback extended a correction that began after the stock peaked near $5 in mid-July 2026, despite a still-positive year-to-date gain of roughly 70%.
- Dilution tied to an August 2026 equity offering weighed on sentiment, and a related lock-up agreement expired in mid-October.
- Positive DENALI Phase 2 survival data and analyst upgrades in October triggered only a partial rebound from multi-month lows.
- Over the trailing quarter, the stock fell approximately 47%, even as the analyst consensus remains a Buy with an average price target near $7.
Zentalis Pharmaceuticals (ZNTL) Company Overview and Market Position
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on developing small-molecule cancer therapeutics. Its lead candidate, azenosertib (ZN-c3), is a potentially first-in-class, orally bioavailable inhibitor of WEE1, a kinase that regulates cell-cycle checkpoints. By blocking WEE1, the drug is designed to force cancer cells with damaged DNA into mitotic catastrophe and cell death.
The company is advancing azenosertib as a biomarker-driven treatment for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), a population estimated to represent about half of all PROC patients and one that currently lacks an approved targeted therapy. Zentalis is also evaluating the asset in earlier lines of ovarian cancer and other tumor types. The company has no approved products and generates no product revenue, funding its operations through equity financings and collaborations. As of September 30, 2025, Zentalis reported cash, cash equivalents, and marketable securities of $280.7 million, with a projected runway into late 2027.
Zentalis Pharmaceuticals (ZNTL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ZNTL moved from a closing price of $3.11 on September 18, 2026, to approximately $2.38, a decline of about 23.6%. The move was not a single sharp selloff but rather a steady drift lower through late September and the first half of October, with the stock touching a recent low near $2.13 on October 16 before rebounding.
The broader picture is similar but steeper. Over the trailing three-month period, ZNTL fell from roughly $4.50 in late July to about $2.38, a decline of approximately 47%. This longer view reflects a strong first-half rally that peaked near $5 in mid-July, followed by a sharp August reset and a continued grind lower. Despite the recent weakness, the stock remains up roughly 70% year-to-date.
What Drove ZNTL Stock Price in the Last 30 Days
Several verified developments shaped the recent move, even though they were not enough to offset persistent selling pressure. On October 5, 2026, Leerink Partners assumed coverage of Zentalis with an Outperform rating and raised its price target to $8 from $4, arguing the market was underappreciating the azenosertib opportunity. HC Wainwright separately reiterated its Buy rating with a $10 price target.
On October 19, the company reported positive interim overall survival data from Part 1b of the DENALI Phase 2 trial. Patients with Cyclin E1-positive platinum-resistant ovarian cancer achieved a median overall survival of 15.8 months, compared with 7.5 months in the Cyclin E1-negative group, with no new safety signals. The results were scheduled for presentation at ESMO 2026, and shares rose on the news.
Despite these catalysts, the stock's 30-day decline was driven primarily by an overhang from an equity offering completed in August 2026. The resulting share dilution, combined with the expiration of a related lock-up agreement in mid-October and broader risk-off sentiment across clinical-stage small-cap biotechnology, kept buyers cautious. The late-October rebound only partially recovered earlier losses.
What Drove ZNTL Stock Performance Over the Last Quarter
The quarterly decline reflects a reversal after a strong run-up. In the first half of 2026, positive clinical momentum, FDA alignment on trial design, and expectations around the azenosertib program lifted ZNTL from roughly $1.30 at the start of the year to a July peak near $5.
The inflection came in mid-August, when the stock dropped sharply from about $4.15 to $3.56 in a single session, coinciding with a dilutive follow-on equity offering. Lock-up and restricted-period disclosures tied to that offering reference TD Securities and Guggenheim Securities as underwriters. Following the raise, the stock traded lower for weeks as investors absorbed the dilution and awaited fresh catalysts. The decline through September and October continued even as analyst targets and clinical data remained supportive, underscoring how financing dynamics and small-cap sentiment can outweigh fundamentals in the near term.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that scan markets across hundreds of tickers. While Tickeron offers a broad library of AI trading bots, only the top-performing and most relevant strategies appear in this section. Each bot varies in its approach, holding timeframe, and performance metrics, allowing users to compare momentum, swing, and trend-following strategies side by side. For investors tracking volatile clinical-stage names, these tools provide an additional lens on price action and signal quality. Explore the page to see which automated strategies are currently gaining attention.
ZNTL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the azenosertib development timeline is the central driver for ZNTL. The company expects to complete enrollment across the DENALI Part 2 cohorts and report a topline readout in the first half of 2027. A positive result could support an accelerated approval pathway, subject to FDA feedback.
Investors should also monitor progress on ASPENOVA, the randomized Phase 3 confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC. Additional data presentations, including the ESMO 2026 survival update, and any guidance on the Cyclin E1 companion diagnostic will be closely watched. On the financial side, cash runway into late 2027 and any future capital-raising activity remain important risk factors, along with broader small-cap biotech sentiment and regulatory milestones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZNTL in -8.19% downward trend, sliding for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZNTL declined for three days, in 274 of 310 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for ZNTL moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Aroon Indicator for ZNTL entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZNTL's RSI Oscillator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 67 cases where ZNTL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ZNTL just turned positive on October 19, 2026. Looking at past instances where ZNTL's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +12.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZNTL advanced for three days, in 214 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ZNTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.555) is normal, around the industry mean (2.988). P/E Ratio (-1.204) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (6.812) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ZNTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer
Industry Biotechnology